Dermata Therapeutics Ownership

DRMA Stock  USD 0.39  0.01  2.50%   
Dermata Therapeutics shows 3.76 percent of its outstanding shares held by insiders and 6.18 percent owned by other corporate entities.
Some institutional investors establish a significant position in stocks such as Dermata Therapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Dermata Therapeutics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
As of March 28, 2024, Dividends Paid is expected to decline to about 1.8 M. The current year's Common Stock Shares Outstanding is expected to grow to about 3.1 M, whereas Net Loss is forecasted to decline to (9.1 M).
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dermata Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
For information on how to trade Dermata Stock refer to our How to Trade Dermata Stock guide.

Dermata Stock Ownership Analysis

The company has price-to-book (P/B) ratio of 0.23. Some equities with similar Price to Book (P/B) outperform the market in the long run. Dermata Therapeutics recorded a loss per share of 2.67. The entity had not issued any dividends in recent years. The firm had 1:16 split on the 14th of March 2023. Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company was incorporated in 2014 and is headquartered in San Diego, California. Dermata Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8 people. To learn more about Dermata Therapeutics call the company at 858 800 2543 or check out https://www.dermatarx.com.
Besides selling stocks to institutional investors, Dermata Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Dermata Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Dermata Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Dermata Therapeutics Quarterly Liabilities And Stockholders Equity

7.98 Million

Roughly 4.0% of Dermata Therapeutics are currently held by insiders. Unlike Dermata Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Dermata Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Dermata Therapeutics' insider trades

Dermata Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Dermata Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Dermata Therapeutics backward and forwards among themselves. Dermata Therapeutics' institutional investor refers to the entity that pools money to purchase Dermata Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Armistice Capital, Llc2023-12-31
218 K
Acadian Asset Management Llc2023-12-31
55.2 K
Virtu Financial Llc2023-12-31
13.5 K
Geode Capital Management, Llc2023-12-31
12.2 K
Tower Research Capital Llc2023-12-31
6.4 K
Wells Fargo & Co2023-12-31
703
Susquehanna International Group, Llp2023-09-30
0.0
Hcr Wealth Advisors2023-09-30
0.0
Two Sigma Securities, Llc2023-12-31
0.0
Ubs Group Ag2023-12-31
0.0
Citadel Advisors Llc2023-09-30
0.0
Note, although Dermata Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Dermata Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Dermata Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Dermata Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Dermata Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Pair Trading with Dermata Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Dermata Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dermata Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Dermata Stock

  0.73MBRX Moleculin Biotech Upward RallyPairCorr
  0.75MCRB Seres Therapeutics Financial Report 14th of May 2024 PairCorr

Moving against Dermata Stock

  0.77DNTH Dianthus Therapeutics Symbol ChangePairCorr
  0.73MRK Merck Company Fiscal Quarter End 31st of March 2024 PairCorr
  0.72MDWD Mediwound Financial Report 4th of June 2024 PairCorr
  0.68MGNX MacroGenics Financial Report 14th of May 2024 PairCorr
  0.63EQ Equillium Financial Report 9th of May 2024 PairCorr
The ability to find closely correlated positions to Dermata Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Dermata Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Dermata Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Dermata Therapeutics to buy it.
The correlation of Dermata Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Dermata Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Dermata Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Dermata Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Dermata Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dermata Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dermata Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dermata Therapeutics Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dermata Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
For information on how to trade Dermata Stock refer to our How to Trade Dermata Stock guide.
You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Complementary Tools for Dermata Stock analysis

When running Dermata Therapeutics' price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Is Dermata Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dermata Therapeutics. If investors know Dermata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dermata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.67)
Return On Assets
(0.67)
Return On Equity
(1.26)
The market value of Dermata Therapeutics is measured differently than its book value, which is the value of Dermata that is recorded on the company's balance sheet. Investors also form their own opinion of Dermata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dermata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dermata Therapeutics' market value can be influenced by many factors that don't directly affect Dermata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dermata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dermata Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dermata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.